Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $298.59 million. The enterprise value is $265.05 million.
Important Dates
The last earnings date was Wednesday, March 5, 2025, after market close.
| Earnings Date | Mar 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 98.87 million shares outstanding. The number of shares has increased by 41.58% in one year.
| Current Share Class | 98.87M |
| Shares Outstanding | 98.87M |
| Shares Change (YoY) | +41.58% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 4.67% |
| Owned by Institutions (%) | 47.16% |
| Float | 94.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.55 |
| Forward PS | 5.57 |
| PB Ratio | -4.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.68
| Current Ratio | 4.68 |
| Quick Ratio | 4.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.22% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -37.27% |
| Revenue Per Employee | $405,359 |
| Profits Per Employee | -$310,824 |
| Employee Count | 142 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 2.79 |
Taxes
| Income Tax | -14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.34% in the last 52 weeks. The beta is 2.76, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 2.76 |
| 52-Week Price Change | -26.34% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 3.78 |
| Relative Strength Index (RSI) | 50.92 |
| Average Volume (20 Days) | 1,359,673 |
Short Selling Information
The latest short interest is 9.98 million, so 10.09% of the outstanding shares have been sold short.
| Short Interest | 9.98M |
| Short Previous Month | 11.09M |
| Short % of Shares Out | 10.09% |
| Short % of Float | 10.59% |
| Short Ratio (days to cover) | 6.77 |
Income Statement
In the last 12 months, AQST had revenue of $57.56 million and -$44.14 million in losses. Loss per share was -$0.51.
| Revenue | 57.56M |
| Gross Profit | 39.69M |
| Operating Income | -30.77M |
| Pretax Income | -25.76M |
| Net Income | -44.14M |
| EBITDA | -30.03M |
| EBIT | -30.77M |
| Loss Per Share | -$0.51 |
Full Income StatementBalance Sheet
The company has $71.55 million in cash and $38.00 million in debt, giving a net cash position of $33.54 million or $0.34 per share.
| Cash & Cash Equivalents | 71.55M |
| Total Debt | 38.00M |
| Net Cash | 33.54M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | -60.16M |
| Book Value Per Share | -0.66 |
| Working Capital | 69.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.76 million and capital expenditures -$159,000, giving a free cash flow of -$35.92 million.
| Operating Cash Flow | -35.76M |
| Capital Expenditures | -159,000 |
| Free Cash Flow | -35.92M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 68.95%, with operating and profit margins of -53.46% and -76.68%.
| Gross Margin | 68.95% |
| Operating Margin | -53.46% |
| Pretax Margin | -76.70% |
| Profit Margin | -76.68% |
| EBITDA Margin | -52.17% |
| EBIT Margin | -53.46% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.58% |
| Shareholder Yield | -41.58% |
| Earnings Yield | -14.78% |
| FCF Yield | -12.03% |
Analyst Forecast
The average price target for AQST is $10.57, which is 250.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.57 |
| Price Target Difference | 250.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 35.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -3.4 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 3 |